Effect of Quinapril on In-Stent Restenosis and Relation to Plasma Apoptosis Signaling Molecules

Scatterplots of the differences between baseline and follow-up values of sFas and sFasL plasma levels in the quinapril and the control groups. Positive values denote increases in plasma apoptotic signaling molecule levels. Note that substantially more patients in the quinapril group experienced increases in plasma sFas and sFasL levels 6 months after stenting than in the placebo group.

Relation of change in plasma sFas levels to late luminal loss in the quinapril and placebo groups. In quinapril-treated patients, there was a significant negative correlation between the change in plasma sFas levels obtained from the left anterior descending coronary artery and late luminal loss (r = −0.14, p = 0.015). No such correlation was observed in the placebo group.